$414.86
1.49% yesterday
Nasdaq, Oct 09, 10:01 pm CET
ISIN
US92532F1003
Symbol
VRTX

Vertex Pharmaceuticals Stock price

$414.86
+18.38 4.64% 1M
-67.44 13.98% 6M
+12.16 3.02% YTD
-53.11 11.35% 1Y
+120.32 40.85% 3Y
+144.91 53.68% 5Y
+304.86 277.15% 10Y
+393.57 1,848.61% 20Y
Nasdaq, Closing price Thu, Oct 09 2025
-6.29 1.49%
ISIN
US92532F1003
Symbol
VRTX
Industry

Key metrics

Basic
Market capitalization
$106.4b
Enterprise Value
$100.0b
Net debt
-
Cash
$6.4b
Shares outstanding
256.3m
Valuation (TTM | estimate)
P/E
29.5 | 22.5
P/S
9.3 | 8.7
EV/Sales
8.8 | 8.2
EV/FCF
28.6
P/B
6.2
Financial Health
Equity Ratio
72.8%
Return on Equity
-3.3%
ROCE
22.3%
ROIC
27.2%
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$11.4b | $12.2b
EBITDA
$4.6b | $5.5b
EBIT
$4.4b | $5.4b
Net Income
$3.6b | $4.7b
Free Cash Flow
$3.5b
Growth (TTM | estimate)
Revenue
10.5% | 10.9%
EBITDA
3.8% | 20.5%
EBIT
4.2% | 22.7%
Net Income
842.5% | 980.8%
Free Cash Flow
345.5%
Margin (TTM | estimate)
Gross
86.1%
EBITDA
40.5% | 45.4%
EBIT
38.8%
Net
31.9% | 38.6%
Free Cash Flow
30.7%
More
EPS
$14.0
FCF per Share
$13.7
Short interest
1.8%
Employees
6k
Rev per Employee
$1.8m
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Vertex Pharmaceuticals forecast:

25x Buy
64%
13x Hold
33%
1x Sell
3%

Analyst Opinions

39 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
64%
Hold
33%
Sell
3%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
11,419 11,419
10% 10%
100%
- Direct Costs 1,587 1,587
13% 13%
14%
9,832 9,832
10% 10%
86%
- Selling and Administrative Expenses 1,570 1,570
17% 17%
14%
- Research and Development Expense 3,833 3,833
13% 13%
34%
4,627 4,627
4% 4%
41%
- Depreciation and Amortization 200 200
4% 4%
2%
EBIT (Operating Income) EBIT 4,427 4,427
4% 4%
39%
Net Profit 3,638 3,638
843% 843%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Positive
The Motley Fool
2 days ago
Warren Buffett famously said that he and his investing managers "attempt to be fearful when others are greedy, and to be greedy only when others are fearful." With the stock market near a record high, many investors are a lot greedier than they are fearful right now.
Neutral
The Motley Fool
3 days ago
Earlier this year, all three major indexes -- the S&P 500, the Nasdaq, and the Dow Jones Industrial Average -- slid as President Donald Trump announced his plan to impose tariffs on imports. Investors worried this would result in higher costs for U.S. companies as they import their goods made abroad -- and this might sink earnings.
Neutral
Business Wire
4 days ago
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Th...
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today